HHS’ Biomedical Advanced Research and Development Authority (BARDA) awarded a US$51 million contract to Emergent BioSolutions, Inc. “for the development of a new anthrax vaccine using the protective antigen (rPA) to stimulate a protective immune response that neutralizes the anthrax toxins.” The potential total value of the five-year award could be US$186.6 million. In the first two years of the contract, Emergent will develop the final vaccine formulation and test its stability. http://www.businesswire.com/news/home/20100917005739/en/BARDA-Awards-51-Million-Contract-Generation-Anthrax